DUSA Pharmaceuticals, Inc. to Host First Quarter Financial Results and Corporate Highlights Conference Call
For release at 8:00 a.m.
DUSA PHARMACEUTICALS, INC. TO HOST
FIRST QUARTER FINANCIAL RESULTS
AND CORPORATE HIGHLIGHTS CONFERENCE CALL
Wilmington, Mass. - May 2, 2008 - DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on Wednesday, May 7 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Wednesday, May 7 - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
435.871.6103
A recorded replay of the call will be available
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately one hour following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReachTM and Nicomide®. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, Mass. Please visit the company's website at www.dusapharma.com for more information.
For further information contact:
Shari Lovell, Director, Shareholder Services
Tel: 978.657.7500 Ext. 1121